Shengjian Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shengjian Zhang has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Yu Chen
Materdicine Lab School of Life Sciences Shanghai University Shanghai China
6 shared publications Zhuang Liu
Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China
6 shared publications- Biqiang Zheng
Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
5 shared publications - Chunmeng Wang
Department of Musculoskeletal Oncology, Bone and Soft Tissue Sarcomas Centre , Fudan University Shanghai Cancer Centre , Fudan University , Shanghai , China , fudan.edu.cn
5 shared publications - Ilia N. Buhtoiarov
Division of Pediatric Hematology/Oncology/BMT, Pediatric Institute Cleveland Clinic Cleveland Ohio USA
5 shared publications - Jianrong Zhang
Department of General Practice and Primary Care & Collaborative Centre for Genomic Cancer Medicine, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia
5 shared publications
Latest Publications
- Open Access
- 13 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1734379
Exploring the recurrence and metastasis of breast invasive ductal carcinoma based on machine learning and survival analysis
Objective: Invasive ductal carcinoma (IDC), the predominant histopathological subtype comprising about 80% of breast malignancies, continues to pose a significant clinical challenge due to frequent recurrence. Existing relapse prediction models remain limited in accuracy and generalizability. This study aimed to construct and validate machine learning–based models for predicting 5-year (short- to medium term) recurrence and metastasis risk in IDC, based on recurrence-free survival (RFS) analysis. Methods: A total of 640 IDC cases diagnosed between January 2017 and December 2019 were enrolled, data were partitioned into three sets: the training set (n = 303) from Fudan University Shanghai Cancer Center; the validation set (n = 217) from Shaoxing Central Hospital; and the test set (n = 120) from Zhejiang Cancer Hospital. Independent prognostic factors were identified through univariate and multivariate Cox regression analyses. Three predictive strategies were implemented: evaluating recurrence risk, distinguishing local from distant recurrence, and identifying metastatic sites. Light Gradient Boosting Machine (LGBM), XGBoost (XGB), Random Forest (RF), k-Nearest Neighbor (KNN), Neural Network (NN), and Support Vector Machine (SVM) were trained and validated. Results: The median follow-up duration was 5.7 years. Multivariate Cox regression analyses identified multiple factors significantly associated with RFS, including the rad-score, Ki-67 index, lymph node metastasis, tumor histological grade, and breast cancer family history in first- or second-degree relatives (all p < 0.05). In contrast, age, menopausal status, and molecular subtype showed no significant association with recurrence risk in this cohort ( p = 0.987, p = 0.987, and p = 0.960, respectively). The clinical-radiomic nomogram demonstrated strong in predictive IDC recurrence. The XGBoost model demonstrated robust and consistent predictive performance across all cohorts, achieving AUCs of 0.842, 0.848, and 0.912 on the training, validation, and test sets, respectively. On the independent test set, the model attained an accuracy of 93.8%, sensitivity of 96.3%, and specificity of 79.6%.Furthermore, density plots of the radiomic score and Ki-67 index effectively differentiated between local recurrence, bone metastasis, and metastases to other organs. Patients with lymph node metastasis and high histological grade demonstrated a higher frequency of metastases to distant organs, accounting for most cases and emphasizing the contrast with local recurrence and bone metastasis. Patients with a breast cancer family history displayed a distinct pattern of bone metastasis. Conclusion: This study underscores the utility of machine learning models in forecasting recurrence and metastatic behavior in IDC. The clinical-radiomic nomograms proved valuable for individualized surgical and therapeutic decision-making in IDC patients.
- 13 March 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1734379
Open AccessExploring the recurrence and metastasis of breast invasive ductal carcinoma based on machine learning and survival analysis
Objective: Invasive ductal carcinoma (IDC), the predominant histopathological subtype comprising about 80% of breast malignancies, continues to pose a significant clinical challenge due to frequent recurrence. Existing relapse prediction models remain limited in accuracy and generalizability. This study aimed to construct and validate machine learning–based models for predicting 5-year (short- to medium term) recurrence and metastasis risk in IDC, based on recurrence-free survival (RFS) analysis. Methods: A total of 640 IDC cases diagnosed between January 2017 and December 2019 were enrolled, data were partitioned into three sets: the training set (n = 303) from Fudan University Shanghai Cancer Center; the validation set (n = 217) from Shaoxing Central Hospital; and the test set (n = 120) from Zhejiang Cancer Hospital. Independent prognostic factors were identified through univariate and multivariate Cox regression analyses. Three predictive strategies were implemented: evaluating recurrence risk, distinguishing local from distant recurrence, and identifying metastatic sites. Light Gradient Boosting Machine (LGBM), XGBoost (XGB), Random Forest (RF), k-Nearest Neighbor (KNN), Neural Network (NN), and Support Vector Machine (SVM) were trained and validated. Results: The median follow-up duration was 5.7 years. Multivariate Cox regression analyses identified multiple factors significantly associated with RFS, including the rad-score, Ki-67 index, lymph node metastasis, tumor histological grade, and breast cancer family history in first- or second-degree relatives (all p < 0.05). In contrast, age, menopausal status, and molecular subtype showed no significant association with recurrence risk in this cohort ( p = 0.987, p = 0.987, and p = 0.960, respectively). The clinical-radiomic nomogram demonstrated strong in predictive IDC recurrence. The XGBoost model demonstrated robust and consistent predictive performance across all cohorts, achieving AUCs of 0.842, 0.848, and 0.912 on the training, validation, and test sets, respectively. On the independent test set, the model attained an accuracy of 93.8%, sensitivity of 96.3%, and specificity of 79.6%.Furthermore, density plots of the radiomic score and Ki-67 index effectively differentiated between local recurrence, bone metastasis, and metastases to other organs. Patients with lymph node metastasis and high histological grade demonstrated a higher frequency of metastases to distant organs, accounting for most cases and emphasizing the contrast with local recurrence and bone metastasis. Patients with a breast cancer family history displayed a distinct pattern of bone metastasis. Conclusion: This study underscores the utility of machine learning models in forecasting recurrence and metastatic behavior in IDC. The clinical-radiomic nomograms proved valuable for individualized surgical and therapeutic decision-making in IDC patients.
- 5 August 2025
- Published by Springer Nature in Immunologic Research
- Vol. 73 (1) , 1-9
Immunoglobulin G4-related sclerosing mastitis: MRI findings and the literature review
Immunoglobulin G4-related disease (IgG4-RD) is a rare immune-mediated fibro-inflammatory condition that can affect nearly any organ, with breast involvement (IgG4-related sclerosing mastitis, IgG4-RM) being exceptionally uncommon. This disease primarily affects middle-aged to elderly women and is frequently misdiagnosed as malignancy due to non-specific clinical and imaging features. We report a case of a 44-year-old woman with a painless right breast mass showing hypoechoic ultrasound findings and magnetic resonance imaging (MRI) characteristics, including a high ADC value and homogeneous enhancement with a persistent time-intensity curve (TIC). Histopathology confirmed IgG4-RM, with no recurrence after 12 months. A review of 24 published lectures highlights the diagnostic challenges and imaging variability of IgG4-RM.
- 5 August 2025
- Published by Springer Nature in Immunologic Research
- Vol. 73 (1) , 1-9
Immunoglobulin G4-related sclerosing mastitis: MRI findings and the literature review
Immunoglobulin G4-related disease (IgG4-RD) is a rare immune-mediated fibro-inflammatory condition that can affect nearly any organ, with breast involvement (IgG4-related sclerosing mastitis, IgG4-RM) being exceptionally uncommon. This disease primarily affects middle-aged to elderly women and is frequently misdiagnosed as malignancy due to non-specific clinical and imaging features. We report a case of a 44-year-old woman with a painless right breast mass showing hypoechoic ultrasound findings and magnetic resonance imaging (MRI) characteristics, including a high ADC value and homogeneous enhancement with a persistent time-intensity curve (TIC). Histopathology confirmed IgG4-RM, with no recurrence after 12 months. A review of 24 published lectures highlights the diagnostic challenges and imaging variability of IgG4-RM.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Table S2. Characteristics of patients with resected undifferentiated pleomorphic sarcoma (UPS) in the real-world report.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Table S2. Characteristics of patients with resected undifferentiated pleomorphic sarcoma (UPS) in the real-world report.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Figure S1. Kaplan-Meier Curve showing the 1-year real-world recurrence-free survival (rwRFS) rate in UPS patients with and without adjuvant anlotinib therapy.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Figure S1. Kaplan-Meier Curve showing the 1-year real-world recurrence-free survival (rwRFS) rate in UPS patients with and without adjuvant anlotinib therapy.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Data from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Purpose:We aimed to investigate the efficacy and safety of anlotinib as adjuvant targeted therapy for completely resected localized high-grade soft-tissue sarcomas (STS).Patients and Methods:Patients with localized high-grade STS after complete resection were randomly assigned in a 1:1 ratio to receive either oral 12 mg anlotinib or placebo once daily on days 1 to 14 every 21 days as a cycle, with up to six cycles until disease relapse, unmanageable toxicity, or death. The efficacy and safety were analyzed. This trial was the first trial exploring adjuvant targeted therapy for STS (NCT03951571).Results:Between June 2019 and November 2023, 88 patients were randomly assigned to receive anlotinib (n = 44) or placebo (n = 44). With a median follow-up of 30.95 months, the 1- and 2-year disease-free survival rates were 88% and 77% in the anlotinib group compared with 64% and 58% in the placebo group, respectively. Compared with patients treated with surgery alone, patients receiving adjuvant anlotinib combined with surgery had a reduced risk of disease recurrence [HR, 0.47; 95% confidence interval (CI), 0.22–1.00; P = 0.0445]. Based on the tumor histology, the reduced risk of disease recurrence with anlotinib versus placebo was observed in patients with myxofibrosarcoma (HR, 0.54; 95% CI, 0.17–1.65; P = 0.2698) and undifferentiated pleomorphic sarcoma (HR, 0.58; 95% CI, 0.12–2.87; P = 0.4971). Four patients discontinued anlotinib: two for proteinuria/hematuria (2/44, 5%) and two for poor healing of surgical wound (2/44, 5%).Conclusions:Compared with surgery alone, adjuvant anlotinib following surgery reduces the incidence of disease relapse in localized high-grade STS, with acceptable toxicity.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Purpose:We aimed to investigate the efficacy and safety of anlotinib as adjuvant targeted therapy for completely resected localized high-grade soft-tissue sarcomas (STS).Patients and Methods:Patients with localized high-grade STS after complete resection were randomly assigned in a 1:1 ratio to receive either oral 12 mg anlotinib or placebo once daily on days 1 to 14 every 21 days as a cycle, with up to six cycles until disease relapse, unmanageable toxicity, or death. The efficacy and safety were analyzed. This trial was the first trial exploring adjuvant targeted therapy for STS (NCT03951571).Results:Between June 2019 and November 2023, 88 patients were randomly assigned to receive anlotinib (n = 44) or placebo (n = 44). With a median follow-up of 30.95 months, the 1- and 2-year disease-free survival rates were 88% and 77% in the anlotinib group compared with 64% and 58% in the placebo group, respectively. Compared with patients treated with surgery alone, patients receiving adjuvant anlotinib combined with surgery had a reduced risk of disease recurrence [HR, 0.47; 95% confidence interval (CI), 0.22–1.00; P = 0.0445]. Based on the tumor histology, the reduced risk of disease recurrence with anlotinib versus placebo was observed in patients with myxofibrosarcoma (HR, 0.54; 95% CI, 0.17–1.65; P = 0.2698) and undifferentiated pleomorphic sarcoma (HR, 0.58; 95% CI, 0.12–2.87; P = 0.4971). Four patients discontinued anlotinib: two for proteinuria/hematuria (2/44, 5%) and two for poor healing of surgical wound (2/44, 5%).Conclusions:Compared with surgery alone, adjuvant anlotinib following surgery reduces the incidence of disease relapse in localized high-grade STS, with acceptable toxicity.
- Open Access
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Table S1. Representativeness of Study Participants.
- 1 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Supplementary Table S1. Representativeness of Study Participants.
- 7 February 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (7) , 1194-1203
Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Purpose: We aimed to investigate the efficacy and safety of anlotinib as adjuvant targeted therapy for completely resected localized high-grade soft-tissue sarcomas (STS). Patients and Methods: Patients with localized high-grade STS after complete resection were randomly assigned in a 1:1 ratio to receive either oral 12 mg anlotinib or placebo once daily on days 1 to 14 every 21 days as a cycle, with up to six cycles until disease relapse, unmanageable toxicity, or death. The efficacy and safety were analyzed. This trial was the first trial exploring adjuvant targeted therapy for STS (NCT03951571). Results: Between June 2019 and November 2023, 88 patients were randomly assigned to receive anlotinib (n = 44) or placebo (n = 44). With a median follow-up of 30.95 months, the 1- and 2-year disease-free survival rates were 88% and 77% in the anlotinib group compared with 64% and 58% in the placebo group, respectively. Compared with patients treated with surgery alone, patients receiving adjuvant anlotinib combined with surgery had a reduced risk of disease recurrence [HR, 0.47; 95% confidence interval (CI), 0.22–1.00; P = 0.0445]. Based on the tumor histology, the reduced risk of disease recurrence with anlotinib versus placebo was observed in patients with myxofibrosarcoma (HR, 0.54; 95% CI, 0.17–1.65; P = 0.2698) and undifferentiated pleomorphic sarcoma (HR, 0.58; 95% CI, 0.12–2.87; P = 0.4971). Four patients discontinued anlotinib: two for proteinuria/hematuria (2/44, 5%) and two for poor healing of surgical wound (2/44, 5%). Conclusions: Compared with surgery alone, adjuvant anlotinib following surgery reduces the incidence of disease relapse in localized high-grade STS, with acceptable toxicity.
- 7 February 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (7) , 1194-1203
Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Purpose: We aimed to investigate the efficacy and safety of anlotinib as adjuvant targeted therapy for completely resected localized high-grade soft-tissue sarcomas (STS). Patients and Methods: Patients with localized high-grade STS after complete resection were randomly assigned in a 1:1 ratio to receive either oral 12 mg anlotinib or placebo once daily on days 1 to 14 every 21 days as a cycle, with up to six cycles until disease relapse, unmanageable toxicity, or death. The efficacy and safety were analyzed. This trial was the first trial exploring adjuvant targeted therapy for STS (NCT03951571). Results: Between June 2019 and November 2023, 88 patients were randomly assigned to receive anlotinib (n = 44) or placebo (n = 44). With a median follow-up of 30.95 months, the 1- and 2-year disease-free survival rates were 88% and 77% in the anlotinib group compared with 64% and 58% in the placebo group, respectively. Compared with patients treated with surgery alone, patients receiving adjuvant anlotinib combined with surgery had a reduced risk of disease recurrence [HR, 0.47; 95% confidence interval (CI), 0.22–1.00; P = 0.0445]. Based on the tumor histology, the reduced risk of disease recurrence with anlotinib versus placebo was observed in patients with myxofibrosarcoma (HR, 0.54; 95% CI, 0.17–1.65; P = 0.2698) and undifferentiated pleomorphic sarcoma (HR, 0.58; 95% CI, 0.12–2.87; P = 0.4971). Four patients discontinued anlotinib: two for proteinuria/hematuria (2/44, 5%) and two for poor healing of surgical wound (2/44, 5%). Conclusions: Compared with surgery alone, adjuvant anlotinib following surgery reduces the incidence of disease relapse in localized high-grade STS, with acceptable toxicity.
- Open Access
- 28 November 2024
- Published by Springer Nature in Cancer Imaging
- Vol. 24 (1) , 1-10
CT radiomics and human-machine hybrid system for differentiating mediastinal lymphomas from thymic epithelial tumors
Background: It is difficult for radiologists, especially junior radiologists with limited experience to make differential diagnoses between mediastinal lymphomas and thymic epithelial tumors (TETs) due to the overlapping imaging features. The purpose of this study was to develop and validate a CT-based clinico-radiomics model for differentiating lymphomas from TETs and to investigate whether a human-machine hybrid system can assist junior radiologists in improving their diagnostic performance. Methods: The patients who underwent contrast-enhanced chest CT and pathologically confirmed with lymphoma or TET at two centers from January 2011 to December 2019 and from January 2017 to December 2021 were retrospectively included and split as training/validation set and external test set, respectively. Clinical and radiomic signatures were pre-selected by elastic-net, and the models were established with the selected signatures using ensemble learning. Three radiologists independently reviewed CT images and assessed each case of the external test set with knowledge of the relevant clinical information. The diagnoses of reader 1, reader 2, and reader 3 were compared with those of the models in the external test set and further separately input to the model’s ensemble process as a human-machine system to make final decisions in the external test set. The improvement of diagnostic performance of radiologists by human-machine system was evaluated by the area under the receiver operating characteristic curve and increase rate. Results: A total of 95 patients (51 with lymphomas and 44 with TETs) at Center 1 and 94 (52 with lymphomas and 42 with TETs) at Center 2 were enrolled and divided into training/validation sets and external test set, respectively. The diagnostic performance of the clinico-radiomics model has outperformed the junior radiologists and senior radiologist in AUC (clinico-radiomics model: 0.85 (0.76,0.92); reader 2: 0.70 (0.60,0.80); reader 3: 0.60 (0.49,0.71), reader 1: 0.76 (0.66,0.86), respectively) in the external test set. The human-machine hybrid system demonstrated significant increases in AUC (reader 1 + model: 0.87 (0.79,0.94), an increase of 14%; reader 2 + model: 0.86 (0.77,0.93), an increase of 23%; reader 3 + model: 0.84 (0.76,0.91), an increase of 40%), compared to the human performance alone. Conclusions: The clinico-radiomics model outperformed three radiologists in differentiating lymphomas from TETs on CT. The use of the human-machine hybrid system significantly improved the performance of radiologists, especially junior radiologists. It provides a real-time decision tool to reduce bias and mistakes in radiologist diagnosis and enhances the diagnostic confidence of junior radiologists. This attempt may lead to more human-machine hybrid systems being explored in the diagnosis of different diseases to drive future clinical applications.
- 28 November 2024
- Published by Springer Nature in Cancer Imaging
- Vol. 24 (1) , 1-10
Open AccessCT radiomics and human-machine hybrid system for differentiating mediastinal lymphomas from thymic epithelial tumors
Background: It is difficult for radiologists, especially junior radiologists with limited experience to make differential diagnoses between mediastinal lymphomas and thymic epithelial tumors (TETs) due to the overlapping imaging features. The purpose of this study was to develop and validate a CT-based clinico-radiomics model for differentiating lymphomas from TETs and to investigate whether a human-machine hybrid system can assist junior radiologists in improving their diagnostic performance. Methods: The patients who underwent contrast-enhanced chest CT and pathologically confirmed with lymphoma or TET at two centers from January 2011 to December 2019 and from January 2017 to December 2021 were retrospectively included and split as training/validation set and external test set, respectively. Clinical and radiomic signatures were pre-selected by elastic-net, and the models were established with the selected signatures using ensemble learning. Three radiologists independently reviewed CT images and assessed each case of the external test set with knowledge of the relevant clinical information. The diagnoses of reader 1, reader 2, and reader 3 were compared with those of the models in the external test set and further separately input to the model’s ensemble process as a human-machine system to make final decisions in the external test set. The improvement of diagnostic performance of radiologists by human-machine system was evaluated by the area under the receiver operating characteristic curve and increase rate. Results: A total of 95 patients (51 with lymphomas and 44 with TETs) at Center 1 and 94 (52 with lymphomas and 42 with TETs) at Center 2 were enrolled and divided into training/validation sets and external test set, respectively. The diagnostic performance of the clinico-radiomics model has outperformed the junior radiologists and senior radiologist in AUC (clinico-radiomics model: 0.85 (0.76,0.92); reader 2: 0.70 (0.60,0.80); reader 3: 0.60 (0.49,0.71), reader 1: 0.76 (0.66,0.86), respectively) in the external test set. The human-machine hybrid system demonstrated significant increases in AUC (reader 1 + model: 0.87 (0.79,0.94), an increase of 14%; reader 2 + model: 0.86 (0.77,0.93), an increase of 23%; reader 3 + model: 0.84 (0.76,0.91), an increase of 40%), compared to the human performance alone. Conclusions: The clinico-radiomics model outperformed three radiologists in differentiating lymphomas from TETs on CT. The use of the human-machine hybrid system significantly improved the performance of radiologists, especially junior radiologists. It provides a real-time decision tool to reduce bias and mistakes in radiologist diagnosis and enhances the diagnostic confidence of junior radiologists. This attempt may lead to more human-machine hybrid systems being explored in the diagnosis of different diseases to drive future clinical applications.
- Open Access
- 10 July 2024
- Published by Springer Nature in Insights into Imaging
- Vol. 15 (1) , 1-12
Differentiating between benign and malignant breast lesions using dual-energy CT-based model: development and validation
Objectives: To develop and validate a dual-energy CT (DECT)-based model for noninvasively differentiating between benign and malignant breast lesions detected on DECT. Materials and methods: This study prospectively enrolled patients with suspected breast cancer who underwent dual-phase contrast-enhanced DECT from July 2022 to July 2023. Breast lesions were randomly divided into the training and test cohorts at a ratio of 7:3. Clinical characteristics, DECT-based morphological features, and DECT quantitative parameters were collected. Univariate analyses and multivariate logistic regression were performed to determine independent predictors of benign and malignant breast lesions. An individualized model was constructed. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic ability of the model, whose calibration and clinical usefulness were assessed by calibration curve and decision curve analysis. Results: This study included 200 patients (mean age, 49.9 ± 11.9 years; age range, 22–83 years) with 222 breast lesions. Age, lesion shape, and the effective atomic number (Zeff) in the venous phase were significant independent predictors of breast lesions (all p < 0.05). The discriminative power of the model incorporating these three factors was high, with AUCs of 0.844 (95%CI 0.764–0.925) and 0.791 (95% CI 0.647–0.935) in the training and test cohorts, respectively. The constructed model showed a preferable fitting (all p > 0.05 by the Hosmer-Lemeshow test) and provided enhanced net benefits than simple default strategies within a wide range of threshold probabilities in both cohorts. Conclusion: The DECT-based model showed a favorable diagnostic performance for noninvasive differentiation between benign and malignant breast lesions detected on DECT. Critical relevance statement: The combination of clinical and morphological characteristics and DECT-derived parameter have the potential to identify benign and malignant breast lesions and it may be useful for incidental breast lesions on DECT to decide if further work-up is needed. Key Points: It is important to characterize incidental breast lesions on DECT for patient management. DECT-based model can differentiate benign and malignant breast lesions with good performance. DECT-based model is a potential tool for distinguishing breast lesions detected on DECT. Graphical
- 10 July 2024
- Published by Springer Nature in Insights into Imaging
- Vol. 15 (1) , 1-12
Open AccessDifferentiating between benign and malignant breast lesions using dual-energy CT-based model: development and validation
Objectives: To develop and validate a dual-energy CT (DECT)-based model for noninvasively differentiating between benign and malignant breast lesions detected on DECT. Materials and methods: This study prospectively enrolled patients with suspected breast cancer who underwent dual-phase contrast-enhanced DECT from July 2022 to July 2023. Breast lesions were randomly divided into the training and test cohorts at a ratio of 7:3. Clinical characteristics, DECT-based morphological features, and DECT quantitative parameters were collected. Univariate analyses and multivariate logistic regression were performed to determine independent predictors of benign and malignant breast lesions. An individualized model was constructed. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic ability of the model, whose calibration and clinical usefulness were assessed by calibration curve and decision curve analysis. Results: This study included 200 patients (mean age, 49.9 ± 11.9 years; age range, 22–83 years) with 222 breast lesions. Age, lesion shape, and the effective atomic number (Zeff) in the venous phase were significant independent predictors of breast lesions (all p < 0.05). The discriminative power of the model incorporating these three factors was high, with AUCs of 0.844 (95%CI 0.764–0.925) and 0.791 (95% CI 0.647–0.935) in the training and test cohorts, respectively. The constructed model showed a preferable fitting (all p > 0.05 by the Hosmer-Lemeshow test) and provided enhanced net benefits than simple default strategies within a wide range of threshold probabilities in both cohorts. Conclusion: The DECT-based model showed a favorable diagnostic performance for noninvasive differentiation between benign and malignant breast lesions detected on DECT. Critical relevance statement: The combination of clinical and morphological characteristics and DECT-derived parameter have the potential to identify benign and malignant breast lesions and it may be useful for incidental breast lesions on DECT to decide if further work-up is needed. Key Points: It is important to characterize incidental breast lesions on DECT for patient management. DECT-based model can differentiate benign and malignant breast lesions with good performance. DECT-based model is a potential tool for distinguishing breast lesions detected on DECT. Graphical
- 22 December 2022
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 11 (4) , 1486-1498
Ultrasound-enhanced cascade chemodynamic tumor nanotherapy with lactic acid-enabled hydrogen peroxide self-production
The ultrasound-enhanced cascade chemodynamic therapy with lactic acid-enabled H 2 O 2 self-production, in cooperation with T1-weighted MRI.
- 22 December 2022
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 11 (4) , 1486-1498
Ultrasound-enhanced cascade chemodynamic tumor nanotherapy with lactic acid-enabled hydrogen peroxide self-production
The ultrasound-enhanced cascade chemodynamic therapy with lactic acid-enabled H 2 O 2 self-production, in cooperation with T1-weighted MRI.